Neurothera Labs Inc. NTLX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 680.00K | -- | -- | -- | 927.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 680.00K | -- | -- | -- | 927.00K |
| Cost of Revenue | 196.00K | -- | -- | -- | 535.00K |
| Gross Profit | 484.00K | -- | -- | -- | 392.00K |
| SG&A Expenses | 2.50M | -- | -- | -- | 1.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.48M | -- | -- | -- | 4.37M |
| Operating Income | -4.80M | -- | -- | -- | -3.44M |
| Income Before Tax | -6.36M | -- | -- | -- | -4.77M |
| Income Tax Expenses | 19.00K | -- | -- | -- | 5.00K |
| Earnings from Continuing Operations | -6.38 | -- | -- | -- | -4.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 307.00K | -- | -- | -- | 1.27M |
| Net Income | -6.08M | -- | -- | -- | -3.50M |
| EBIT | -4.80M | -- | -- | -- | -3.44M |
| EBITDA | -4.62M | -- | -- | -- | -3.17M |
| EPS Basic | -1.46 | -- | -- | -- | -0.74 |
| Normalized Basic EPS | -0.56 | -- | -- | -- | -0.17 |
| EPS Diluted | -1.46 | -- | -- | -- | -0.74 |
| Normalized Diluted EPS | -0.56 | -- | -- | -- | -0.17 |
| Average Basic Shares Outstanding | 19.46M | -- | -- | -- | 13.56M |
| Average Diluted Shares Outstanding | 23.98M | -- | -- | -- | 13.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |